Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 15, 2011

Takeda Forges Contract Research Pact with Covance and Quintiles

  • Takeda Pharmaceuticals signed partnerships with Covance and Quintiles to together plan and execute global development programs to support new compounds in all therapeutic areas except oncology. A global program-level sourcing strategy is expected to increase operational efficiency, Takeda explains. Through these relationships, Takeda will move toward a fully virtual outsourcing model.

    The company will have access to the clinical development capabilities and central laboratory services of Covance and Quintiles. Each partner company will provide dedicated resources to support Takeda’s development pipeline. Combining the expertise and capabilities of all three companies will improve productivity and facilitate Takeda’s global growth, the firm notes.

    “Takeda is focused on growing its global drug development footprint, especially in Asia, while at the same time ensuring quality and increasing efficiency of our operations,” remarks Robert Ahlbrandt, Ph.D., svp, global development operations for Takeda’s pharmaceutical development division. “Our new strategic partnerships with Covance and Quintiles will improve the agility and productivity of our drug development activities, helping us to deliver innovative new medicines to patients globally.”

    Takeda Pharmaceuticals is a wholly owned subsidiary of Japanese company Takeda Pharmaceutical. Based at Deerfield, IL, it mainly acts as a hub for R&D and commercial activities in the Americas and Europe.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »